Last reviewed · How we verify
Course A3 + Vin
Course A3 + Vin is a combination chemotherapy regimen combining doxorubicin, cyclophosphamide, and vincristine used to treat pediatric cancers.
Course A3 + Vin is a combination chemotherapy regimen combining doxorubicin, cyclophosphamide, and vincristine used to treat pediatric cancers. Used for Pediatric cancers (specific indication not clearly defined in available data).
At a glance
| Generic name | Course A3 + Vin |
|---|---|
| Sponsor | Children's Cancer Group, China |
| Drug class | Multi-agent chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a multi-agent chemotherapy combination where doxorubicin and cyclophosphamide act as alkylating/intercalating agents to damage cancer cell DNA, while vincristine is a vinca alkaloid that disrupts microtubule formation and mitotic spindle function. The combination approach targets multiple mechanisms of cancer cell proliferation and is designed to improve efficacy in pediatric malignancies.
Approved indications
- Pediatric cancers (specific indication not clearly defined in available data)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Course A3 + Vin CI brief — competitive landscape report
- Course A3 + Vin updates RSS · CI watch RSS
- Children's Cancer Group, China portfolio CI